Sarah Tannehill-Gregg

Sarah Tannehill-Gregg currently serves as Vice President of Preclinical Development at Kelonia Therapeutics, starting in January 2024. Previously, Sarah held roles such as Senior Director at Pfizer, overseeing toxicology for the Legacy GBT portfolio in Hematology, and Senior Director/Head of Toxicology at Global Blood Therapeutics just before the company’s acquisition. At Takeda, Sarah progressed through various senior leadership positions in toxicology with extensive oversight of oncology programs, while at Amgen and Bristol-Myers Squibb, Sarah focused on comparative biology, safety sciences, and veterinary pathology. Sarah holds a PhD in Experimental Pathology and a DVM in Veterinary Medicine from The Ohio State University, as well as a BA in Zoology from Miami University.